| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| INCYIncyte Corporation | 20.66B | 105.24 | 701.60 | 14.76% | 24.69% | 25.55% | 1.21% | 0.01 |
| TGTXTG Therapeutics, Inc. | 4.88B | 30.71 | 204.73 | 40.8% | 13.31% | 21.87% | 1.14 | |
| AGIOAgios Pharmaceuticals, Inc. | 1.62B | 27.80 | 2.39 | 36.07% | -8.96% | -31.24% | 0.04 | |
| CLRBCellectar Biosciences, Inc. | 15.48M | 3.65 | -0.09 | -200.99% | 0.03 | |||
| CASICASI Pharmaceuticals, Inc. | 21.37M | 1.04 | -0.41 | -15.77% | -183.93% | -301.8% | 11.96 | |
| VORVor Biopharma Inc. | 308.06M | 14.06 | -0.41 | -94.52% | 0.33 | |||
| FATEFate Therapeutics, Inc. | 121.12M | 1.05 | -0.64 | -78.55% | -21.87% | -66.69% | 0.27 | |
| KPTIKaryopharm Therapeutics Inc. | 121.95M | 6.66 | -0.71 | -0.55% | -87.43% |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 19.36M | 21.38M | 33.2M | 45.78M | 31.1M | 20.76M | 35.58M |
| Revenue Growth % | - | 0.1% | 0.55% | 0.38% | -0.32% | -0.33% | 0.71% |
| Cost of Goods Sold | 28.59M | 0 | 78.44M | 0 | 0 | 7.74M | 0 |
| COGS % of Revenue | 1.48% | - | 2.36% | - | - | 0.37% | - |
| Gross Profit | -9.23M | 21.38M | -45.24M | 45.78M | 31.1M | 13.02M | 35.58M |
| Gross Margin % | -0.48% | 1% | -1.36% | 1% | 1% | 0.63% | 1% |
| Gross Profit Growth % | - | 3.32% | -3.12% | 2.01% | -0.32% | -0.58% | 1.73% |
| Operating Expenses | 35.75M | 56.83M | 15.2M | 127.92M | 160.63M | 152.05M | 155.2M |
| OpEx % of Revenue | 1.85% | 2.66% | 0.46% | 2.79% | 5.17% | 7.33% | 4.36% |
| Selling, General & Admin | 7.16M | 8.77M | 15.2M | 33.25M | 42.79M | 42.08M | 42.12M |
| SG&A % of Revenue | 0.37% | 0.41% | 0.46% | 0.73% | 1.38% | 2.03% | 1.18% |
| Research & Development | 28.59M | 48.06M | 78.44M | 94.67M | 117.84M | 117.71M | 110.64M |
| R&D % of Revenue | 1.48% | 2.25% | 2.36% | 2.07% | 3.79% | 5.67% | 3.11% |
| Other Operating Expenses | -7K | 0 | -78.44M | 0 | 0 | -7.74M | 2.44M |
| Operating Income | -16.39M | -35.45M | -60.45M | -82.13M | -129.53M | -139.03M | -119.61M |
| Operating Margin % | -0.85% | -1.66% | -1.82% | -1.79% | -4.17% | -6.7% | -3.36% |
| Operating Income Growth % | - | -1.16% | -0.71% | -0.36% | -0.58% | -0.07% | 0.14% |
| EBITDA | -12.82M | -33.86M | -58.83M | -80.64M | -127.86M | -131.29M | -117.8M |
| EBITDA Margin % | -0.66% | -1.58% | -1.77% | -1.76% | -4.11% | -6.33% | -3.31% |
| EBITDA Growth % | - | -1.64% | -0.74% | -0.37% | -0.59% | -0.03% | 0.1% |
| D&A (Non-Cash Add-back) | 3.57M | 1.59M | 1.62M | 1.49M | 1.68M | 7.74M | 1.82M |
| EBIT | -16.39M | -33.3M | -60.45M | -81.75M | -125.96M | -129.84M | -105.19M |
| Net Interest Income | 685K | 1.83M | -836K | -1.76M | 1.36M | 8.44M | 14.43M |
| Interest Income | 685K | 1.83M | 393K | 387K | 3.58M | 9.81M | 14.43M |
| Interest Expense | 0 | 0 | 1.23M | 2.15M | 2.22M | 1.37M | 0 |
| Other Income/Expense | 678K | 2.16M | -5.26M | -1.76M | 1.36M | 7.82M | 14.43M |
| Pretax Income | -15.71M | -33.3M | -65.71M | -83.89M | -128.18M | -131.21M | -105.19M |
| Pretax Margin % | -0.81% | -1.56% | -1.98% | -1.83% | -4.12% | -6.32% | -2.96% |
| Income Tax | 0 | 804K | 626K | 0 | 0 | 1.28M | 131K |
| Effective Tax Rate % | 1% | 1.02% | 1.01% | 1% | 1% | 1.01% | 1% |
| Net Income | -15.71M | -34.1M | -66.33M | -83.89M | -128.18M | -132.49M | -105.32M |
| Net Margin % | -0.81% | -1.59% | -2% | -1.83% | -4.12% | -6.38% | -2.96% |
| Net Income Growth % | - | -1.17% | -0.95% | -0.26% | -0.53% | -0.03% | 0.21% |
| Net Income (Continuing) | -15.71M | -34.1M | -66.33M | -83.89M | -128.18M | -132.49M | -105.32M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.06 | -0.79 | -1.54 | -1.82 | -2.62 | -2.67 | -1.52 |
| EPS Growth % | - | 0.25% | -0.95% | -0.18% | -0.44% | -0.02% | 0.43% |
| EPS (Basic) | -1.06 | -0.79 | -1.54 | -1.82 | -2.62 | -2.67 | -1.52 |
| Diluted Shares Outstanding | 42.09M | 42.99M | 43.06M | 46.04M | 48.86M | 49.64M | 69.37M |
| Basic Shares Outstanding | 14.79M | 42.99M | 43.06M | 46.04M | 48.86M | 49.64M | 69.37M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 123.53M | 96.77M | 381.01M | 325.69M | 287.56M | 271.19M | 257.77M |
| Cash & Short-Term Investments | 36.31M | 90.55M | 371.69M | 309.28M | 276.15M | 253.68M | 244.9M |
| Cash Only | 36.31M | 90.55M | 181.73M | 76.12M | 29.75M | 126.59M | 55.5M |
| Short-Term Investments | 0 | 0 | 189.96M | 233.16M | 246.4M | 127.09M | 189.41M |
| Accounts Receivable | 86.44M | 4.62M | 4.48M | 5.72M | 1.47M | 11.8M | 3.1M |
| Days Sales Outstanding | 1.63K | 78.92 | 49.3 | 45.57 | 17.29 | 207.49 | 31.82 |
| Inventory | 0 | 0 | 0 | 0 | -60.96M | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 70.89M | 5.71M | 9.76M |
| Total Non-Current Assets | 22.96M | 21.49M | 19.13M | 181.08M | 143.28M | 105.26M | 91.83M |
| Property, Plant & Equipment | 20.38M | 18.92M | 16.55M | 35.05M | 77.52M | 71.09M | 63.38M |
| Fixed Asset Turnover | 0.95x | 1.13x | 2.01x | 1.31x | 0.40x | 0.29x | 0.56x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 2.58M | 0 | 0 | 142.2M | 60.96M | 28.01M | 22.36M |
| Other Non-Current Assets | 0 | 2.58M | 2.58M | 3.82M | 4.8M | 6.17M | 6.1M |
| Total Assets | 146.49M | 118.26M | 400.14M | 506.76M | 430.84M | 376.45M | 349.6M |
| Asset Turnover | 0.13x | 0.18x | 0.08x | 0.09x | 0.07x | 0.06x | 0.10x |
| Asset Growth % | - | -0.19% | 2.38% | 0.27% | -0.15% | -0.13% | -0.07% |
| Total Current Liabilities | 23.95M | 33.64M | 43.85M | 51.25M | 44.55M | 42.77M | 45.18M |
| Accounts Payable | 1.15M | 5.38M | 5.68M | 4.51M | 1.17M | 1.45M | 1.33M |
| Days Payables Outstanding | 14.73 | - | 26.44 | - | - | 68.22 | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 2.29M | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 1.26M | 3.33M | 4.19M | 5.5M | 3.11M | 9.39M | 9.3M |
| Current Ratio | 5.16x | 2.88x | 8.69x | 6.36x | 6.46x | 6.34x | 5.71x |
| Quick Ratio | 5.16x | 2.88x | 8.69x | 6.36x | 7.82x | 6.34x | 5.71x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 202.29M | 196.58M | 75.5M | 65.91M | 97.06M | 87.57M | 88.44M |
| Long-Term Debt | 0 | 0 | 10.05M | 10.77M | 9.2M | 0 | 0 |
| Capital Lease Obligations | 13.75M | 12.87M | 11.83M | 30.78M | 70.97M | 65.76M | 59.98M |
| Deferred Tax Liabilities | -13.75M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 111M | 111M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 226.24M | 230.22M | 119.35M | 117.16M | 141.61M | 130.34M | 133.62M |
| Total Debt | 14.48M | 13.75M | 22.92M | 42.88M | 87.15M | 70.98M | 65.76M |
| Net Debt | -21.83M | -76.8M | -158.81M | -33.24M | 57.4M | -55.61M | 10.26M |
| Debt / Equity | - | - | 0.08x | 0.11x | 0.30x | 0.29x | 0.30x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -49.19x | -38.29x | -58.45x | -101.26x | - |
| Total Equity | -79.75M | -111.96M | 280.79M | 389.61M | 289.23M | 246.11M | 215.99M |
| Equity Growth % | - | -0.4% | 3.51% | 0.39% | -0.26% | -0.15% | -0.12% |
| Book Value per Share | -1.89 | -2.60 | 6.52 | 8.46 | 5.92 | 4.96 | 3.11 |
| Total Shareholders' Equity | -79.75M | -111.96M | 280.79M | 389.61M | 289.23M | 246.11M | 215.99M |
| Common Stock | 1K | 0 | 4K | 5K | 5K | 6K | 7K |
| Retained Earnings | -83.39M | -117.49M | -183.82M | -267.71M | -395.89M | -528.38M | -633.7M |
| Treasury Stock | -6.14M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.5M | 0 | 13K | -775K | -4.14M | -127K | 53K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -16.98M | 55.61M | -67.25M | -86.97M | -105.94M | -106.84M | -65.16M |
| Operating CF Margin % | -0.88% | 2.6% | -2.03% | -1.9% | -3.41% | -5.15% | -1.83% |
| Operating CF Growth % | - | 4.28% | -2.21% | -0.29% | -0.22% | -0.01% | 0.39% |
| Net Income | -15.71M | -34.1M | -66.33M | -83.89M | -128.18M | -132.49M | -105.32M |
| Depreciation & Amortization | 1.27M | 1.59M | 1.62M | 1.49M | 1.68M | 1.88M | 1.82M |
| Stock-Based Compensation | 582K | 1.64M | 3.43M | 21.51M | 30.02M | 27.23M | 29.66M |
| Deferred Taxes | 66K | 350K | 5.58M | 1.88M | 0 | 0 | 0 |
| Other Non-Cash Items | 2.37M | 1.14M | 1.63M | 2.13M | 7.32M | 3.48M | 1.03M |
| Working Capital Changes | -5.56M | 84.98M | -13.18M | -30.09M | -16.78M | -6.94M | 7.65M |
| Change in Receivables | -84.94M | 81.81M | 139K | -1.23M | 4.24M | -10.33M | 8.7M |
| Change in Inventory | -2.22M | 2.17M | -1.58M | -2.63M | 0 | 0 | 0 |
| Change in Payables | 578K | 4.23M | 467K | -1.18M | -3.33M | 273K | -119K |
| Cash from Investing | 36.92M | -1.62M | -190.5M | -189.34M | 58.42M | 158.35M | -51.27M |
| Capital Expenditures | -2.69M | -1.35M | -650K | -1.28M | -5.5M | -1.71M | -180K |
| CapEx % of Revenue | 0.14% | 0.06% | 0.02% | 0.03% | 0.18% | 0.08% | 0.01% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 39.61M | 0 | -189.85M | -188.06M | 63.92M | 0 | 0 |
| Cash from Financing | 1.96M | 244K | 348.93M | 171.4M | 1.15M | 45.49M | 45.34M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | -63K | 274K | -3.45M | 1.94M | 370K | 426K | 1.16M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -19.67M | 54.27M | -67.9M | -88.24M | -111.44M | -108.55M | -65.34M |
| FCF Margin % | -1.02% | 2.54% | -2.05% | -1.93% | -3.58% | -5.23% | -1.84% |
| FCF Growth % | - | 3.76% | -2.25% | -0.3% | -0.26% | 0.03% | 0.4% |
| FCF per Share | -0.47 | 1.26 | -1.58 | -1.92 | -2.28 | -2.19 | -0.94 |
| FCF Conversion (FCF/Net Income) | 1.08x | -1.63x | 1.01x | 1.04x | 0.83x | 0.81x | 0.62x |
| Interest Paid | 0 | 0 | 820K | 0 | 0 | 990K | 0 |
| Taxes Paid | 0 | 1.09M | 143K | 0 | 0 | 1M | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -78.58% | -25.03% | -37.76% | -49.5% | -45.58% |
| Return on Invested Capital (ROIC) | - | - | -37.17% | -25.76% | -27.64% | -38.83% | -43.05% |
| Gross Margin | -47.66% | 100% | -136.3% | 100% | 100% | 62.72% | 100% |
| Net Margin | -81.14% | -159.48% | -199.83% | -183.23% | -412.19% | -638.34% | -295.96% |
| Debt / Equity | - | - | 0.08x | 0.11x | 0.30x | 0.29x | 0.30x |
| Interest Coverage | - | - | -49.19x | -38.29x | -58.45x | -101.26x | - |
| FCF Conversion | 1.08x | -1.63x | 1.01x | 1.04x | 0.83x | 0.81x | 0.62x |
| Revenue Growth | - | 10.42% | 55.25% | 37.93% | -32.08% | -33.25% | 71.44% |
C4 Therapeutics, Inc. (CCCC) reported $30.1M in revenue for fiscal year 2024. This represents a 55% increase from $19.4M in 2018.
C4 Therapeutics, Inc. (CCCC) grew revenue by 71.4% over the past year. This is strong growth.
C4 Therapeutics, Inc. (CCCC) reported a net loss of $119.1M for fiscal year 2024.
C4 Therapeutics, Inc. (CCCC) has a return on equity (ROE) of -45.6%. Negative ROE indicates the company is unprofitable.
C4 Therapeutics, Inc. (CCCC) had negative free cash flow of $95.1M in fiscal year 2024, likely due to heavy capital investments.